Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses

• DOI: 10.1038/srep22094
• Publication Date: 2016-02-25T10:56:25Z
• Authors: David A. Muller; Frances E. Pearson; Germain J.P. Fern...; Christiana Agyei-...; Nick S. Owens; Simon R. Corrie; Michael L. Crichton; Jonathan C.J. Wei; William C. Weldon; M. Steven Oberste; Paul R. Young; Mark A. F. Kendall
• Keywords: Inactivated Poliovirus Vaccine; Poliomyelitis eradication; Intramuscular injection

Abstract Polio eradication is progressing rapidly and the live attenuated Sabin strains in oral poliovirus vaccine (OPV) are being removed sequentially, starting with type 2 April 2016. For risk mitigation, countries introducing inactivated (IPV) into routine vaccination programs. After 2016, monovalent OPV will be available for outbreak control. Because current IPV not suitable house-to-house campaigns (the intramuscular injections require health professionals), we developed a high-density microprojection array, Nanopatch, delivered (IPV2) to skin. To assess immunogenicity of performed dose-matched study rats, comparing IPV2 by injection or Nanopatch immunisation. A single dose 0.2 D-antigen units elicited protective levels antibodies 100% animals. However, animals receiving IM required at least 3 immunisations reach same neutralising antibody titres. This level reduction (1/40th full dose) unprecedented delivery. The ease administration coupled observed this points as potential tool facilitating inexpensive mass campaigns.